SHANG.FOS.PHARM.GR.H YC 1 (08HH) — Net Asset Quality Index
SHANG.FOS.PHARM.GR.H YC 1 (08HH) has a Net Asset Quality Index of 51.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €122.97 Billion minus total liabilities of €59.30 Billion yields net assets of €63.67 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check SHANG.FOS.PHARM.GR.H YC 1 (08HH) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
SHANG.FOS.PHARM.GR.H YC 1 Net Asset Quality Index Over Time (2021–2025)
This chart shows how SHANG.FOS.PHARM.GR.H YC 1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the index stands at 51.8%, representing net assets of €63.67 Billion against total assets of €122.97 Billion EUR. See SHANG.FOS.PHARM.GR.H YC 1 (08HH) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 08HH company net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 51.5% | €61.84 Billion | €120.05 Billion | €58.21 Billion | ▲ +0.5 pp |
| 2024 | 51.0% | €59.93 Billion | €117.46 Billion | €57.53 Billion | ▲ +1.1 pp |
| 2023 | 49.9% | €56.62 Billion | €113.47 Billion | €56.85 Billion | ▼ -0.6 pp |
| 2022 | 50.5% | €54.11 Billion | €107.16 Billion | €53.05 Billion | ▼ -1.4 pp |
| 2021 | 51.9% | €48.38 Billion | €93.31 Billion | €44.93 Billion | — |